上海医药氨磺必利口崩片纳入国家医保目录

Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd., successfully negotiated to include Amisulpride orally disintegrating tablets in the National Medical Insurance Directory, effective from January 1, 2026, to December 31, 2027 [1] Group 1 - Amisulpride orally disintegrating tablets are an improved formulation of Amisulpride tablets, which were launched by Sanofi in France in 1986, and are used for the treatment of adult schizophrenia [1] - As of the announcement date, there are no other companies in China that have launched Amisulpride orally disintegrating tablets [1] - Shanghai Shenyang Pharmaceutical Co., Ltd. became the marketing authorization holder for Amisulpride orally disintegrating tablets after receiving approval from the National Medical Products Administration in October 2025 [1]